Retinopathy of Prematurity — International Classification (ICROP3)
International Classification of Retinopathy of Prematurity 3rd revision (Chiang 2021). Combines Zone (I most posterior, III peripheral nasal), Stage (1–5), and Plus disease; Type 1 (treat) and Type 2 (observe) ROP are the ETROP definitions (2003). Used to time treatment in screened preterm neonates.
Score interpretation
→ Continue UK ROP screening protocol per RCPCH/BAPM/RCOphth: weekly–fortnightly fundus exams until vascularisation reaches Zone III or 36 weeks PMA / discharge — whichever later.
→ Weekly screening. Treatment not yet indicated. Anticipate spontaneous regression but be ready to escalate.
→ Treatment within 48–72 hours: laser photocoagulation (gold standard) or intravitreal anti-VEGF (ranibizumab — RAINBOW trial; bevacizumab). Joint neonatology + ophthalmology decision. Long-term follow-up for myopia and late detachment.
→ Urgent paediatric vitreoretinal referral. Lens-sparing vitrectomy ± scleral buckle (Stage 4A/4B) or vitrectomy with capsulectomy (Stage 5) — outcomes guarded for Stage 5. Lifelong follow-up; visual rehabilitation; family support.
Interpretation bands for the ROP. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Ranibizumab · Anti-VEGF (intravitreal injection)
- Bevacizumab (Intravitreal) · Anti-VEGF (Vascular Endothelial Growth Factor Inhibitor)
- Aflibercept 2mg/0.05mL Intravitreal Injection (Eylea) · Anti-VEGF agent (intravitreal)
- Faricimab (Intravitreal) · Anti-VEGF and Anti-Ang-2 — Bispecific Monoclonal Antibody
- Brolucizumab (Intravitreal) · Anti-VEGF — Single-chain Antibody Fragment (scFv)
- Pegaptanib Sodium · Anti-VEGF (RNA Aptamer) — Neovascular AMD
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.